Terms: = Lymphoma AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Prognosis
69 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways.
Zhang Y; Wang ZZ; Han AQ; Yang MY; Zhu LX; Pan FM; Wang Y
Hepatobiliary Pancreat Dis Int; 2024 Apr; 23(2):195-209. PubMed ID: 37806848
[TBL] [Abstract] [Full Text] [Related]
3. Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels.
Bahlmann LC; Xue C; Chin AA; Skirzynska A; Lu J; Thériault B; Uehling D; Yerofeyeva Y; Peters R; Liu K; Chen J; Martel AL; Yaffe M; Al-Awar R; Goswami RS; Ylanko J; Andrews DW; Kuruvilla J; Laister RC; Shoichet MS
Biomaterials; 2023 Jun; 297():122121. PubMed ID: 37075613
[TBL] [Abstract] [Full Text] [Related]
4. Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition.
Li X; Wang F; Zhang X; Sun Q; Kuang E
PLoS Pathog; 2023 Jan; 19(1):e1011103. PubMed ID: 36656913
[TBL] [Abstract] [Full Text] [Related]
5. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract] [Full Text] [Related]
6. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract] [Full Text] [Related]
7. Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma.
Rej A; Paladhi A; Daripa S; Sarkar D; Bhattacharyya S; Mondal I; Hira SK
Int Immunopharmacol; 2023 Jan; 114():109521. PubMed ID: 36470118
[TBL] [Abstract] [Full Text] [Related]
8. Netrin-1 induces the anti-apoptotic and pro-survival effects of B-ALL cells through the Unc5b-MAPK axis.
Huang L; An X; Zhu Y; Zhang K; Xiao L; Yao X; Zeng X; Liang S; Yu J
Cell Commun Signal; 2022 Aug; 20(1):122. PubMed ID: 35974411
[TBL] [Abstract] [Full Text] [Related]
9. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract] [Full Text] [Related]
10. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
[TBL] [Abstract] [Full Text] [Related]
11. [Clinicopathological characteristics of SMARCB1(INI1)-deficient sinonasal carcinoma].
Wang JY; Bai YP; Xing L; Piao YS; He XJ; Yue CL; Zhao XL; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1240-1245. PubMed ID: 34719161
[No Abstract] [Full Text] [Related]
12. The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell lymphoma.
Xu L; Qin Y; Liu M; Jiao J; Tu D; Zhang M; Yan D; Song X; Sun C; Zhu F; Wang X; Sang W; Xu K
Anticancer Agents Med Chem; 2022; 22(8):1530-1540. PubMed ID: 34503423
[TBL] [Abstract] [Full Text] [Related]
13. Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia.
Artico LL; Laranjeira ABA; Campos LW; Corrêa JR; Zenatti PP; Carvalheira JBC; Brambilla SR; Nowill AE; Brandalise SR; Yunes JA
Blood Adv; 2021 Sep; 5(18):3633-3646. PubMed ID: 34438446
[TBL] [Abstract] [Full Text] [Related]
14. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Gao J; Wang MY; Ren Y; Lwin T; Li T; Yan JC; Sotomayor EM; Duckett DR; Shah BD; Shain KH; Zhao X; Tao J
Haematologica; 2022 May; 107(5):1119-1130. PubMed ID: 34162179
[TBL] [Abstract] [Full Text] [Related]
15. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
Castillo JJ; Beltran BE; Malpica L; Marques-Piubelli ML; Miranda RN
Leuk Lymphoma; 2021 Dec; 62(12):2845-2853. PubMed ID: 34151703
[TBL] [Abstract] [Full Text] [Related]
16. Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and erk signaling pathways.
Jiang H; Tang J; Qiu L; Zhang Z; Shi S; Xue L; Kui L; Huang T; Nan W; Zhou B; Zhao C; Yu M; Sun Q
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649851
[TBL] [Abstract] [Full Text] [Related]
17. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract] [Full Text] [Related]
18. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract] [Full Text] [Related]
19. Aggressive B-cell lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
20. Role and mechanism of FLNa and UCP2 in the development of cervical cancer.
Wang A; Liu L; Yuan M; Han S; You X; Zhang H; Lei F; Zhang Y
Oncol Rep; 2020 Dec; 44(6):2656-2668. PubMed ID: 33125133
[TBL] [Abstract] [Full Text] [Related]
[Next]
